We recently announced that our team here at CiteAb has expanded our platform to cover multiple reagent types, and today we’re taking a first look at some of our new data. The inhibitors and activators used by life scientists to investigate cellular processes are collectively termed as ‘chemical probes’. They provide vital tools for […]
Our founder, Dr Andrew Chalmers, is leading an Antibody Validation Working Group for the Global Biological Standards Institute (GBSI) focused on improving the validation of antibodies used for ICC. The group is one of nine created by the GBSI with the aim of creating a series of antibody validation guidelines for each of the most […]
New to our series of blogs on antibody research applications, today we are exploring the top targets for ICC, or immunocytochemistry. ICC is the staining and microscopic examination of cells, which are often grown in culture. This is not to be confused with immunohistochemistry (IHC), which involves the staining of tissues with their normal organisation […]
Here at CiteAb we have recently developed our technology so that we can now collate data on multiple reagent types – not just antibodies. This means we can now give a picture of the global market for different types of reagent, in the same way that we have for antibodies. Our founder, Dr Andrew Chalmers, […]
As the vast majority of commercial antibodies are raised against human proteins, we became interested in taking a look at which commercial antibodies are being used by the zebrafish research community. Is the zebrafish research community using a subset of specialist antibodies raised for zebrafish research, or is it relying on anti-human antibodies cross reacting? […]
Last week our founder Dr Andrew Chalmers was in Alpbach for the 8th Affinity Proteomics Meeting, where he presented CiteAb’s latest antibody validation efforts. At the event a huge range of antibody and proteomics science was presented, ranging from exciting new new binders to antibody engineering and therapeutics. Andrew said: “Over the course of the […]
THE DEADLINE FOR APPLICATIONS HAS NOW CLOSED Here at CiteAb we’re looking for a graduate in Computer Science to join our team and help to develop our industry leading data curation, machine learning and search engine technology. Job title: Graduate Developer Location: Bath Salary: Starting £22 – £27k Hours: Full Time. Part […]
THE DEADLINE FOR APPLICATIONS HAS NOW CLOSED Here at CiteAb we’re looking for a graduate in biological sciences or chemistry to join our team and manage some of our key data products. Job title: Data product manager (Biological Sciences or Chemistry) Location: Bath Salary: Competitive (Based on qualifications and experience) Hours: Full […]
We recently announced the winners of the 2017 CiteAb Antibody Awards, and today we feature the winner profile here on our blog for the category of ‘Custom antibody or alternative affinity reagent supplier 2017’. The winners of this category for 2017 are Bio-Rad, headquartered in California, USA, and trading internationally. This category recognises a supplier […]
We recently announced the winners of the 2017 CiteAb Antibody Awards, and today we feature the winner profile here on our blog for the prestigious category of ‘Most Exciting Antibody Validation Initiative 2017’. The winners of this category for 2017 are Abcam, headquartered in the UK and trading internationally. This category was extremely competitive and […]
CiteAb is the largest citation-ranked antibody search engine and database. It provides an impartial way to find and compare antibodies that work.
We use our database of antibody publications to produce unique antibody market data, income from this data allows us to remain free to list and impartial.
Publication metadata is provided by PubMed®, a database of the US National Library of Medicine.
PubMed® is a registered trademark of US National Library of Medicine.
Company registered in England #08530854. VAT #179706954.
In partnership with
© CiteAb 2012-2015. All Rights Reserved.